2018 ANNUAL REPORT
$34 Million in Series D Financing Awarded to PhaseBio
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary disorders
NEW START-UP: Cereius, Inc.
A biotechnology company developing novel approaches to treat solid tumor brain metastases, Cereius’ intellectual property includes next-generation radiolabeling chemistries developed by Dr. Michael Zalutsky, Professor of Radiology, Radiation Oncology and Biomedical Engineering
Successful 1st Year for New Ventures’ MIR Program
OLV’s MIR program didn’t reinvent the start-up wheel — rather, just enabled it to turn faster and more efficiently.
16
NEW START-UPS CREATED
This year we’ve helped grow and develop ventures ranging from gene therapy to machine learning
Element Genomics Acquired by UCB
Novel epigenomic editing techniques to improve understanding of genome structure and function to identify potential new drug targets
NEW START-UP:
Prepped Health
Offering multiple tools for empowering patients to take control of their healthcare journey
NEW START-UP:
Infinia ML
Using advanced machine
learning techniques to solve business challenges